Evidence map›Paper›PMID 38672803›Full record

ArticleLife (Basel, Switzerland)2024

Looking into the Eyes to See the Heart of Chronic Kidney Disease Patients.

Maria Kislikova, Jorge Javier Gaitán-Valdizán, José Antonio Parra Blanco, María Teresa García Unzueta, María Rodríguez Vidriales, Clara Escagedo Cagigas, Vicente Celestino Piñera Haces, María de la Oliva Valentín Muñoz, Adalberto Benito Hernández, Juan Carlos Ruiz San Millan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maria KislikovaImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, 39008 Santander, Spain.ORCID 0000-0002-8387-1607
Jorge Javier Gaitán-ValdizánOphthalmology Department, Marqués de Valdecilla University Hospital-IDIVAL, 39008 Santander, Spain.
José Antonio Parra BlancoRadiology Department, Marqués de Valdecilla University Hospital-IDIVAL, 39008 Santander, Spain.
María Teresa García UnzuetaClinical Laboratory Department, Marqués de Valdecilla University Hospital-IDIVAL, 39008 Santander, Spain.
María Rodríguez VidrialesImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, 39008 Santander, Spain.
Clara Escagedo CagigasImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, 39008 Santander, Spain.
Vicente Celestino Piñera HacesImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, 39008 Santander, Spain.
María de la Oliva Valentín MuñozImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, 39008 Santander, Spain.
Adalberto Benito HernándezImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, 39008 Santander, Spain.
Juan Carlos Ruiz San MillanImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, 39008 Santander, Spain.ORCID 0000-0002-7904-8730
Emilio Rodrigo CalabiaImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, 39008 Santander, Spain.ORCID 0000-0002-2845-5272

Funding

Marqués de Valdecilla University Hospital-IDIVAL research institute MTVAL 18/01Marqués de Valdecilla University Hospital-IDIVAL research institute NEXTVAL 18/09Marqués de Valdecilla University Hospital-IDIVAL research institute TRANSVAL 18/01RICORS2040 RD21/0005/0010
6 · The paper itself

Abstract

In patients with chronic kidney disease (CKD), the main cause of morbidity and mortality is cardiovascular disease (CVD). Both coronary artery calcium scoring by computed tomography (CT) and optical coherence tomography (OCT) are used to identify patients at increased risk for ischemic heart disease, thereby indicating a higher cardiovascular risk profile. Our study aimed to investigate the utility of these techniques in the CKD population. In patients with CKD, OCT was used to measure the choroidal thickness (CHT) and the thickness of the peripapillary retinal nerve fiber layer (pRNFL). A total of 127 patients were included, including 70 men (55%) with an estimated glomerular filtration rate (eGFR) of 39 ± 30 mL/min/1.73 m

Indexed as

cardiac diseasechoroidCKDcoronary diseaseretinal nervetroponin

Identifiers

PMID38672803
PMCPMC11051204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.